BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...partnerships and from the Dompé family. Sergio Dompé is chairman and CEO of Italian pharma Dompé Farmaceutici S.p.A....
BioCentury | Apr 30, 2019
Distillery Therapeutics

Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers

...mouse models of lung cancer. Syntrix Pharmaceuticals has SX-682 in Phase I testing for melanoma. Dompe...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Aug 31, 2018
Clinical News

FDA approves first drug for neurotrophic keratitis

...FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare...
...approved in the U.S. for the indication, according to the agency. A company spokesperson said Dompe...
...has breakthrough therapy, Orphan Drug status and Fast Track designation from FDA for the indication. Dompe...
BioCentury | Aug 22, 2018
Company News

FDA approves first drug for neurotrophic keratitis

...FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare...
...drug approved in the U.S. for the indication, according to the agency. A spokesperson said Dompe...
...Fast Track designation from FDA for the indication. Sandi Wong Recombinant human nerve growth factor (rhNGF), cenegermin (oxervate) Dompe...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...least five companies have small molecule inhibitors of MDM2 in preclinical-Phase I testing for cancer. Dompe...
...Mass. Buck Institute for Research on Aging, Novato, Calif. CanBas Co. Ltd. (Tokyo:4575), Numazu, Japan Dompe...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Aug 16, 2017
Clinical News

EC approves Dompe's Oxervate for keratitis

...The European Commission approved an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin to...
...rolling BLA to FDA for Oxervate, and has begun discussions for regulatory approval in Japan. Dompe...
...Farmaceutici S.p.A. , Milan, Italy Product: Oxervate cenegermin Business: Ophthalmic Chris Lieu cenegermin Oxervate Recombinant human nerve growth factor (rhNGF) Dompe...
BioCentury | May 26, 2017
Clinical News

CHMP recommends Dompe's human nerve growth factor for keratitis

...EMA’s CHMP recommended approval of an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin...
...and has Orphan Drug designation for the indication. EMA reviewed the MAA under accelerated assessment. Dompe...
...cenegermin (Recombinant human nerve growth factor , rhNGF) Business: Ophthalmic Julian Zhu Recombinant human nerve growth factor (rhNGF) Dompe...
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

...no treatment. Next steps include investigating the mechanisms that regulate CXCL1 expression in cancer cells. Dompe...
...diabetics and Phase II testing for metastatic triple-negative breast cancer (TNBC) and renal transplant rejection. Dompe...
Items per page:
1 - 10 of 66
BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

...partnerships and from the Dompé family. Sergio Dompé is chairman and CEO of Italian pharma Dompé Farmaceutici S.p.A....
BioCentury | Apr 30, 2019
Distillery Therapeutics

Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers

...mouse models of lung cancer. Syntrix Pharmaceuticals has SX-682 in Phase I testing for melanoma. Dompe...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Aug 31, 2018
Clinical News

FDA approves first drug for neurotrophic keratitis

...FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare...
...approved in the U.S. for the indication, according to the agency. A company spokesperson said Dompe...
...has breakthrough therapy, Orphan Drug status and Fast Track designation from FDA for the indication. Dompe...
BioCentury | Aug 22, 2018
Company News

FDA approves first drug for neurotrophic keratitis

...FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare...
...drug approved in the U.S. for the indication, according to the agency. A spokesperson said Dompe...
...Fast Track designation from FDA for the indication. Sandi Wong Recombinant human nerve growth factor (rhNGF), cenegermin (oxervate) Dompe...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...least five companies have small molecule inhibitors of MDM2 in preclinical-Phase I testing for cancer. Dompe...
...Mass. Buck Institute for Research on Aging, Novato, Calif. CanBas Co. Ltd. (Tokyo:4575), Numazu, Japan Dompe...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Aug 16, 2017
Clinical News

EC approves Dompe's Oxervate for keratitis

...The European Commission approved an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin to...
...rolling BLA to FDA for Oxervate, and has begun discussions for regulatory approval in Japan. Dompe...
...Farmaceutici S.p.A. , Milan, Italy Product: Oxervate cenegermin Business: Ophthalmic Chris Lieu cenegermin Oxervate Recombinant human nerve growth factor (rhNGF) Dompe...
BioCentury | May 26, 2017
Clinical News

CHMP recommends Dompe's human nerve growth factor for keratitis

...EMA’s CHMP recommended approval of an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin...
...and has Orphan Drug designation for the indication. EMA reviewed the MAA under accelerated assessment. Dompe...
...cenegermin (Recombinant human nerve growth factor , rhNGF) Business: Ophthalmic Julian Zhu Recombinant human nerve growth factor (rhNGF) Dompe...
BioCentury | Jun 30, 2016
Distillery Therapeutics

Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

...no treatment. Next steps include investigating the mechanisms that regulate CXCL1 expression in cancer cells. Dompe...
...diabetics and Phase II testing for metastatic triple-negative breast cancer (TNBC) and renal transplant rejection. Dompe...
Items per page:
1 - 10 of 66